Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CervoMed’s SEC disclosures read like a roadmap for reversing synaptic dysfunction. Every 10-K details how neflamapimod could alter the course of dementia with Lewy bodies, and each 8-K update can pivot market sentiment overnight. If you have ever typed “CervoMed SEC filings explained simply” and still felt lost, this page is built for you.
Stock Titan’s AI reviews each document the moment it hits EDGAR, turning dense scientific language into plain-English highlights. Need “understanding CervoMed SEC documents with AI”? Our summaries point you directly to trial enrollment metrics, cash-runway tables, and risk-factor changes. Compare segments quickly inside a “CervoMed annual report 10-K simplified” view, or drill into drug-development spend in a single click.
All filing types are here with real-time updates:
- “CervoMed quarterly earnings report 10-Q filing” – revenue, R&D burn, and AI-flagged trend charts.
- “CervoMed insider trading Form 4 transactions” and “CervoMed Form 4 insider transactions real-time” – track when neuroscience insiders buy or sell.
- “CervoMed 8-K material events explained” – from interim trial data to FDA feedback.
- “CervoMed proxy statement executive compensation” – see how milestones drive pay packages.
Each section includes “CervoMed earnings report filing analysis” so you can spot shifts in clinical timelines faster than a manual read-through. Whether you’re monitoring “CervoMed executive stock transactions Form 4” before a pivotal readout or validating biomarker-related spend, our expert commentary and AI-powered summaries let you move from document to decision in minutes.
CervoMed Inc. officer reports open-market stock purchases
An officer of CervoMed Inc. (CRVO), serving as Chief Commercial and Business leader, reported buying company common stock in open-market transactions. On 11/17/2025, the officer purchased 3,500 shares at a price of $8.43 per share. On 11/18/2025, the officer purchased an additional 1,500 shares at $7.95 per share.
After these transactions, the officer beneficially owns a total of 15,000 shares of CervoMed common stock, held directly. The filing indicates that the reported transactions were regular stock purchases rather than option exercises or other derivative security activity.
CervoMed Inc. (CRVO) director and 10% owner reported open‑market purchases of common stock. On 11/17/2025, the reporting person bought 10,793 shares of CervoMed common stock at a weighted average price of $8.46 per share in open‑market transactions. On the same date, an additional 10,807 shares were purchased at a weighted average price of $8.46 per share in an individual retirement account held by the reporting person’s spouse. After these transactions, the reporting person beneficially owned 1,484,078 shares directly and 12,500 shares indirectly through the spouse’s IRA, including shares jointly held with the issuer’s President & Chief Executive Officer.
CervoMed Inc. (CRVO) reported insider share purchases by a senior executive. The company’s CFO, General Counsel and Secretary bought 1,000 shares of common stock on 11/17/2025 at $8.45 per share and 2,500 shares on 11/18/2025 at a weighted average price of $8.32 per share in open‑market transactions. Following these transactions, the reporting person beneficially owned 12,500 shares of CervoMed common stock directly.
The filing notes that the 2,500 shares purchased on 11/18/2025 were acquired at prices ranging from $8.26 to $8.38, with the weighted average price reported, and that detailed trade breakdowns are available upon request.
CervoMed Inc. (CRVO) reported insider share purchases by its CEO & President, who is also a director and 10% owner. On 11/17/2025, the reporting person bought 10,807 shares of common stock in open‑market transactions at a weighted average price of $8.46, with actual prices ranging from $8.39 to $8.46. Following this, the reporting person directly beneficially owned 1,484,078 shares.
On the same date, an additional 10,793 shares were purchased at a weighted average price of $8.46 (with prices from $8.38 to $8.50) for the reporting person’s spouse’s IRA, which is reported as indirect ownership of 12,500 shares. The ownership totals also include shares held jointly with the spouse and in a Roth IRA.
CervoMed Inc. (CRVO)
After these transactions, the reporting person beneficially owned 1,471,578 shares of CervoMed common stock directly, with 1,693 shares held indirectly through a spouse's IRA. Some shares are held jointly with the reporting person's spouse, Dr. John Alam, the company's President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported insider buying by its CEO, President, director and 10% owner. On 11/13/2025, the reporting person bought 4,447 shares of common stock in open-market transactions at $7.51 per share. On 11/14/2025, additional open-market purchases included 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA and 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA. Following these transactions, 1,471,578 shares were held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, with separate Roth IRA holdings noted.
CervoMed Inc. (CRVO)10,000 shares of common stock in open-market transactions on 11/14/2025 at a weighted average price of $7.57 per share. Following this transaction, the reporting person beneficially owns 10,000 shares, held directly.
According to the filing, the shares were bought in multiple open-market trades at prices ranging from $7.53 to $7.60 per share. The reporting person has undertaken to provide full details of the number of shares purchased at each separate price within this range upon request.
CervoMed Inc. (CRVO) reported an insider transaction on a Form 4. A director and 10% owner purchased 5,553 shares of common stock in open‑market transactions on 11/12/2025 at a price of $7.35 per share. Following the purchase, the reporting person beneficially owned 1,467,131 shares. The filing notes these shares are held jointly with the reporting person’s spouse, Dr. John Alam, M.D., the company’s President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported an insider stock purchase by its CFO, GC & Secretary, William R. Elder. On 11/12/2025, Elder bought 3,500 shares of common stock in open‑market transactions at $7.44 per share (Transaction Code: P). Following the transaction, his direct holdings total 9,000 shares. The filing was submitted by one reporting person.
CervoMed Inc. (CRVO) insider purchase: The CEO & President, who is also a Director and 10% Owner, bought 5,553 shares of common stock at $7.35 on 11/12/2025 in open‑market transactions. Following the purchase, he beneficially owned 1,467,131 shares, reported as directly held. The filing notes these shares are held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, PharmD, a member of the Board of Directors.
FAQ
What is the current stock price of CervoMed (CRVO)?
What is the market cap of CervoMed (CRVO)?
